PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous ...

Investing.com -- Celldex Therapeutics Inc (NASDAQ:CLDX) reported third-quarter earnings that fell short of analyst expectations on Monday, as the company continues to invest heavily in its pipeline of ...

SKAN Group AG ( ($CH:SKAN) ) has issued an update. SKAN Group AG announced that it will not meet its revenue and profit expectations for 2025 due ...

Chapel Hill and expert on street drugs, was awarded a 2025 MacArthur Fellowship. The so-called “genius grant” comes with an ...

Investing.com -- Oric Pharmaceuticals Inc (NASDAQ:ORIC) stock rose 1.9% in premarket trading Friday after the company published a peer-reviewed research paper on its cancer drug enozertinib in the ...

Sandoz Group Ltd ( ($CH:SDZ) ) has shared an update. Sandoz has announced a strategic agreement to acquire Just-Evotec Biologics EU SAS, enhancing ...

Nabarun Dasgupta, a senior scientist at UNC-Chapel Hill and expert on fatal drug overdoses, was awarded a 2025 MacArthur ...

The changes won’t come about right away, however, with the Government saying the new curriculum won’t be published until ...

Biogen CEO Chris Viehbacher and Travis Murdoch — fellow Canadians — hit it off when Biogen last year bought Murdoch's HI-Bio ...

Jaxsen Stokes is having a breakout junior season at Sierra Canyon, where he has shown both durability and versatility as a ...

With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust ...

This article introduces the field of bioinformatics and its importance as a cornerstone of biological research, as well as ...